References
- Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14–22. doi: 10.1038/sj.leu.2404955
- Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 Apr 28;352(17):1779–1790. doi: 10.1056/NEJMoa051113
- Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270. doi: 10.1371/journal.pmed.0030270
- Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–2390. doi: 10.1056/NEJMoa1311347
- Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405. doi: 10.1056/NEJMoa1312542
- Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014;123(24):3714–3719. doi: 10.1182/blood-2014-03-530865
- Swerdllow S, Campo E, Harris NL. Who classification of tumours of haematopoietic and lymphoid tissues. France: IARC Press; 2008. 2008.
- Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544–1551. doi: 10.1182/blood-2013-11-539098
- Coppolino MG, Woodside MJ, Demaurex N, et al. Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. Nature. 1997;386(6627):843–847. doi: 10.1038/386843a0
- Wu Z, Zhang X, Xu X, et al. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. J Hematol Oncol. 2014;7:48. doi: 10.1186/s13045-014-0048-6
- Trifa AP, Popp RA, Cucuianu A, et al. CALR versus JAK2 mutated essential thrombocythaemia – a report on 141 patients. Br J Haematol. 2015;168(1):151–153. doi: 10.1111/bjh.13076
- Shirane S, Araki M, Morishita S, et al. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica. 2015;100(2):e46–e48. doi: 10.3324/haematol.2014.115113
- Li N, Yao QM, Gale RP, et al. Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations. Leuk Res. 2015;39(5):510–514. doi: 10.1016/j.leukres.2015.02.006
- Ha JS, Kim YK. Calreticulin exon 9 mutations in myeloproliferative neoplasms. Ann Lab Med. 2015;35(1):22–27. doi: 10.3343/alm.2015.35.1.22
- Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014;123(14):2220–2228. doi: 10.1182/blood-2013-11-537167
- Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552–1555. doi: 10.1182/blood-2013-11-538983
- Chi J, Nicolaou KA, Nicolaidou V, et al. Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis. Leukemia. 2014;28(5):1152–1154. doi: 10.1038/leu.2013.382
- Jones AV, Ward D, Lyon M, et al. Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. Leuk Res. 2015;39(1):82–87. doi: 10.1016/j.leukres.2014.11.019